German Christopher Paul 4

What Happened

• Christopher German, Corporate Controller & CAO of Rhythm Pharmaceuticals (RYTM), reported transactions on March 4, 2026. He exercised/converted derivative awards related to a total of 3,000 shares (two entries of 1,500 shares each) and sold 5,614 shares in an open-market transaction.
• Details reported: exercised 1,500 shares at $17.97 per share (cost $26,955) and a separate exercise/conversion of 1,500 shares with $0 cash reported for that entry; sold 5,614 shares at $89.56 per share for total proceeds of $502,790.

Key Details

• Transaction date: 2026-03-04.
• Exercise/Conversion (code M): 1,500 shares at $17.97 (acquired, $26,955); 1,500 shares reported as exercised/converted with $0 proceeds on the filing.
• Sale (code S): 5,614 shares sold on the open market at $89.56 each, proceeds $502,790.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes: F1 notes 21 shares purchased under the company ESPP; F2 describes the related stock option grant (granted Apr 4, 2023) and vesting schedule (25% on Mar 20, 2024, then 6.25% quarterly through Mar 20, 2027).
• Filing timeliness: filing shows report for period ending 2026-03-04 and was filed on 2026-03-06; no late-filing flag indicated in the provided data.

Context

• The filing records both option exercises/conversions (derivative activity) and an open-market sale the same day. The report does not explicitly state whether the sale was part of a cashless exercise, tax-withholding, or an unrelated disposition.
• For retail investors: purchases (ESPP or option exercises funded by the insider) can be a stronger bullish signal than routine sales; in this case the most notable cash activity was the sizable open-market sale (~$502.8K).